Ad to air during Republican Convention

WASHINGTON, DC, USA, July 14, 2016 /EINPresswire.com/ -- An anti-Trump Super PAC will air a 30-second TV ad called “Republixan” during the Republican National Convention in Cleveland. The ad will air 108 times on CNN and Fox News, including 48 prime time slots during the four-day convention.

Yakety-Yak PAC, a newly-formed, Washington, DC-based Super PAC that produced the ad, is targeting Republican women.

The ad is a parody of pharmaceutical commercials and urges Republican women to talk with their doctor about taking a drug called Republixan -- “a little red pill that relieves the stress, guilt and shame associated with voting for Donald Trump.”

According to the PAC, “No rational, thinking woman would vote for Donald Trump unless she was drugged.” Mary Beth Myers, a Republican waitress from Scatasville, Alabama, disagreed, “I seen the ad on Facebook and I don’t need no stinkin’ drug to vote for Mr. Trump!” Actually, Mary Beth is fictional, but there are probably a lot of real Mary Beths out there.

The ad’s director (name withheld for fear of groundless legal retribution) remarked, “This is a great ad, believe me, a great ad. An incredible ad. We’re going to win so many voters, we’re gonna get tired of winning, believe me. It’ll make Trump start bleeding from his whatever.”

In the ad, a narrator warns of side effects such as “tax cuts for the rich; reduced benefits for women, veterans and minorities; cuts in Medicare and Medicaid; cuts in funding for education; a possible war with Iran and other side effects hazardous to the health of our nation.”

This and other ads from the PAC are also scheduled to run in selected swing states later in the campaign. The ads can be seen at www.yakety-yakpac.com.

C. Seder
Yakety-Yak PAC
202 288-5027
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.